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Abstract
Introduction—Rotavirus remains the leading cause of severe diarrhea in children under 5 years 
worldwide. In the US, Rotarix® (RV1) and RotaTeq® (RV5), have been associated with reductions 
in and severity of rotavirus disease. Studies have evaluated the impact of RV1 or RV5 but little is 
known about the impact of incomplete or mixed vaccination upon vaccine effectiveness.
Methods—Case control study to examine association of combined RV1 and RV5 and rotavirus 
acute gastroenteritis, factoring severity of diarrheal disease. Children born after March 1, 2009 
with acute gastroenteritis from three pediatric hospitals in Atlanta, Georgia were approached for 
enrollment. Survey was administered, stool specimen was collected, and vaccination records were 
obtained.
Results—891 of 1127 children with acute gastroenteritis were enrolled. Stool specimens were 
collected from 708 for rotavirus testing; 215 stool samples tested positively for rotavirus. Children 
>12 months of age were more likely to have rotavirus. Children categorized with Vesikari score of 
>11 were almost twice as likely to be rotavirus positive. Prior rotavirus vaccination decreased the 
mean Vesikari score, p < 0.0001. Children with complete single type vaccination were protected 
against rotavirus (OR 0.21, 95% CI: 0.14–0.31, p < 0.0001).
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Conclusion—Complete rotavirus vaccination with a single vaccine type resulted in protection 
against rotavirus diarrhea and decrease in severity of rotavirus gastroenteritis. Incomplete rotavirus 
vaccination either with a single vaccine or mixed vaccination types also provided some protection.
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1. Introduction
Rotavirus remains the leading cause of severe diarrhea world-wide in children under the age 
of 5 years [1]. Recent estimates at 450 million deaths and approximately 2.4 million 
hospitalizations worldwide due to diarrhea [2,3]. Introduction of rotavirus vaccines has been 
associated with reductions in gastroenteritis mortality and rotavirus related hospitalizations 
in middle and high income countries [7]. In the US., there are currently two rotavirus 
vaccines: Rotarix® (GlaxoSmithKline Biologicals; RV1), a live-attenuated, oral, two dose 
rotavirus vaccine and RotaTeq® (Merck & Co., Inc.; RV5), a live-reassortant, oral, three 
dose rotavirus vaccine. In 2006, RV5 was licensed and recommended for US infants by the 
Advisory Committee on Immunization Practices (ACIP), and in 2008, RV1 was licensed and 
recommended for routine vaccination among infants [4]. US studies have demonstrated a 
73% mean annual reduction in the number of rotavirus-positive test results after the 
introduction of rotavirus vaccines [5–10]. In 2008–2009, rotavirus vaccines prevented an 
estimated 30,000–40,000 hospitalizations [11] and 170,000 emergency department visits in 
the US [12]. In developed countries, rotavirus vaccines have demonstrated high efficacy 
against severe rotavirus disease [13] and a decrease in disease severity [14–16]. Rates of 
rotavirus related hospitalizations and emergency department visits were similarly reduced 
between children who received 2 doses of RV5 (incomplete) compared to those who had 
received 3 doses of RV5 (complete) [17].
Although ACIP does not indicate a preference for RV1 or RV5, it does recommend 
completing the vaccine series with the same vaccine type [4]. Since vaccination should not 
be deferred because the product used for a previous dose(s) is unavailable or unknown, 
ACIP recommends that if any dose in the series was RV5 or the vaccine product was 
unknown for any dose in the series, a total of three doses of rotavirus vaccine should be 
administered and all doses should be administered by age 8 months and 0 days [4]. Very 
little has been reported on the effectiveness of mixed vaccine doses [11]. Given differences 
in strain composition between the two vaccine types and seasonal variation in wild-type 
circulating strains, understanding the impact on rotavirus disease burden and severity in 
children who are administered a mixed schedule of RV1 and RV5 is important. Studies have 
demonstrated that RV1 and RV5 exert similar effectiveness against not only most commonly 
circulating strains but homotypic and heterotypic strains which may have seasonal 
variations. The impact of complete or incomplete vaccinations of single type or mixed 
incomplete on the persistence of this immunity is unknown.
We describe the association between a mixed vaccine (complete or incomplete) regimen of 
RV1 and RV5 and a complete regimen with a single vaccine type and protection against 
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rotavirus infection. We also examined the relationship between incomplete and complete 
rotavirus single or mixed vaccine regimens on severity of disease. To our knowledge, this is 
the first study to explicitly address the relationship of rotavirus vaccines when administered 
in mixed vaccine type on rotavirus acute gastroenteritis (AGE).
2. Materials and methods
This was a secondary analysis of a large case control study to examine the association 
between combined dosing of RV1 and RV5 and rotavirus acute gastroenteritis, factoring 
severity of diarrheal disease. Active surveillance was conducted on all children presenting to 
any of the three freestanding pediatric hospitals’ Emergency Departments in Atlanta, 
Georgia. All children who met the following inclusion criteria were approached for 
enrollment: Children whose date of birth was after March 1, 2009 and who were evaluated 
in the emergency department or admitted for hospitalization presenting with symptoms of 
AGE, as defined by having >3 looser than normal stools in a 24 h period but less than 10 
overall days of diarrhea (Only children born after March 1, 2009 were old enough to have 
had the opportunity to receive either rotavirus vaccine when it became available for routine 
infant use in the US). Patients were excluded if they did not speak English or Spanish, were 
immunocompromised, did not meet the study definition for AGE, did not have stool samples 
collected within 14 days of enrollment, and had no vaccination record based on 
documentation from the state immunization registry or provider medical records. A twin 
would be excluded if the other twin had been enrolled and had a stool sample collected. 
Determination of case or control status is based on rotavirus results from stool specimens 
collected on eligible study participants. Cases and controls were not matched by any criteria, 
e.g., age, gender, or race.
The surveillance was conducted from January through June of 2010, 2011, and 2013 at three 
separate dedicated pediatric hospitals in Atlanta, Georgia as previously described. Time 
periods are based on seasonality of rotavirus infections, and since prevalence of rotavirus 
disease alternates between high and low rates with each season, enrollment did not occur in 
2012 as it was projected to be a low rotavirus prevalence year [16].
2.1. Ethical considerations
Once informed consent was obtained by legal guardian, a standardized questionnaire was 
administered as a personal interview by study staff and instructions were provided on how to 
collect the stool specimen. This study was reviewed and approved by institutional review 
boards at the local hospitals, academic institutions, and the Centers for Disease Control and 
Prevention (CDC).
2.2. Survey of study participant characteristics
A questionnaire was administered at the time of enrollment, and a stool sample was 
collected within 14 days of onset of illness. The questionnaire surveyed for demographic 
information, insurance status, signs/symptoms of clinical illness (duration of diarrhea and 
vomiting, maximum number of vomiting and diarrheal episodes in a 24-h period, evidence 
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of fever or dehydration, and treatment administered). Fig. 1 outlines the process for 
determining how study participants were included.
2.3. Laboratory determination of rotavirus status
Rotavirus testing on stool specimens was conducted at the CDC using commercial enzyme 
immunoassay kit, Rotaclone® (Meridian Life Science, Inc., Cincinnati, Ohio) to determine 
whether patients were rotavirus test-positive (cases) or rotavirus test-negative (controls).
2.4. Vaccination status
Immunization status of participants at the time of enrollment was verified by two separate 
mechanisms: queries to the Georgia Registry of Immunization Transactions and written 
documentation provided by each participant’s named healthcare providers. Vaccine 
information was collected for rotavirus and diphtheria-tetanus-acellular pertussis (DTaP). 
Information on vaccination manufacturer, dates of rotavirus vaccine administration, and 
vaccine lot numbers were entered into the relational database [11]. DTaP was selected as a 
proxy for timely receipt of vaccines since the dosing schedule follows rotavirus vaccination 
schedules for the first 3 doses and is widely accepted by parents who might avoid other 
vaccines [18,19].
2.5. Definition for complete rotavirus vaccination
Participants were categorized as complete for RV5 rotavirus vaccination if he/she received 
three doses of RV5 at the time of enrollment, or for those younger than 8 months 0 days of 
age, ACIP recommended number of doses for that particular age at time of enrollment. 
Complete RV1 included those who received two doses of vaccine or two doses of RV1 and 
one dose of RV5 prior to diarrheal onset, or for those younger than 8 months 0 days of age, 
complete vaccination status was assigned if the child received the ACIP recommended 
number of doses for that age at the time of enrollment. Complete mixed dose was defined as 
receiving one dose of RV1 and two doses of RV5 by 8 months 0 days of age or one dose of 
RV1 and one dose of RV5 before 8 months 0 days of age.
2.6. Definition for incomplete rotavirus vaccination
Participants were categorized as having incomplete mixed doses of rotavirus vaccination if 
he/she received only one dose of RV5 and one dose of RV1 after 8 months 0 days of age. 
Incomplete RV5 were those who received one or two doses of RV5 vaccine and no doses of 
RV1 after 8 months 0 days of age. Incomplete RV1 were those who received only one dose 
of RV1 vaccine after 4 months 0 days of age. Definitions used to categorize ‘complete’ and 
‘incomplete’ DTaP vaccination were based on the ACIP recommended vaccination 
schedules for routine and ‘catch-up’ vaccine administration for persons aged 4 months 
through 18 years [20].
2.7. Gastroenteritis severity score
Severity of diarrheal disease was determined using a modified Vesikari scale [21], whereby 
>11 score was categorized as severe [17,22]. Assessment of severity was prospectively 
obtained from health records and survey questionnaire responses given at the time of 
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enrollment. Severe and non-severe patients were further stratified based on whether they 
received RV1, RV5, or a mixed vaccine regimen. The original Vesikari scale accounts for 
duration of illness. However, for the purposes of this study, duration of illness was calculated 
based on the number of days a patient had symptoms on the day of their enrollment, rather 
than following up with patients to determine how long their illness persisted after 
enrollment.
2.8. Statistical analysis
The frequency distributions of study participant demographics, vaccine type and the number 
of doses, and the age at the time of vaccination were determined between cases and controls, 
and significant differences were determined by Chi Square or Fisher’s exact test, whichever 
was appropriate. Bivariate logistic regression analysis was also applied for factors a priori 
considered associated with risk of rotavirus disease. Multivariate logistic regression analysis 
was performed to assess the association between rotavirus disease adjusted for those risk 
factors. Odds ratios and a corresponding 95% CI were calculated for each vaccine group 
complete RV1/RV5, complete mixed, incomplete RV1/RV5, and incomplete mixed. The 
probability density function of rotavirus disease by disease severity was estimated using 
kernel densities [23] and comparison of these densities were performed using bootstrapping 
methods [24]. To compare Vesikari scores between cases and controls, analysis was done 
with two sample t-tests. Wilcoxon rank sum tests were also used comparing Vesikari scores 
by complete mixed and complete single groups. Analyses were performed by using a 
statistical software package (SAS version 9.2 and R version 3.0).
3. Results
During three separate rotavirus seasons (January through June of 2010, 2011, and 2013), 
1127 children who presented with AGE symptoms and met age requirements for enrollment 
were approached for participation. Two hundred and twenty-six (20.1%) legal caregivers or 
parents declined participation leaving 901 (79.9%) who were enrolled. Stool samples were 
successfully obtained from 708 (78.6%) of enrolled participants. Ten subjects were excluded 
from the study after stool was collected for failing to meet study requirements, leaving 698 
subjects for analyses (Fig. 1). Two hundred and fifteen (30.4%) samples tested positively for 
rotavirus and served as the cases. Epidemic curves during the three rotavirus seasons are 
shown in Fig. 2. The majority of cases occurred during February through April of each year.
3.1. Population characteristics
The majority of participants enrolled in the study were Black (403, 57.7%) and had public 
insurance (538, 77.1%). Rates of rotavirus test-positive stools were lower in Hispanic 
children compared to White children (p = 0.0035). The distribution of ages was significantly 
different between rotavirus test-positive cases and rotavirus test-negative controls (p < 
0.0005), with rotavirus test-positive AGE children being older on average (>12 months) than 
rotavirus test-negative children. Twenty-seven percent of children with rotavirus test-positive 
were >2 years of age in comparison to 13.5% of those who were rotavirus test-negative. 
More than half of all study participants (381, 54.6%) had Vesikari score >11 or severe AGE 
(Table 1). Half of the rotavirus test-positive children had not received a prior dose of 
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rotavirus vaccine. No difference was found in complete DTaP vaccination rates between 
cases and controls (p = 0.11).
3.2. Rotavirus disease and vaccination status
Children with Vesikari score >11 were more likely to be rotavirus test-positive (OR 1.99, 
95% CI: 1.42–2.77) (Table 2). Distribution of Vesikari scores was significantly different 
with rotavirus test-positive cases having higher Vesikari scores than controls (p < 0.0001, 
Fig. 3). Children with complete rotavirus vaccination were protected against rotavirus, 
regardless of whether or not the vaccination was from a single type of vaccine or mixed 
types (complete mixed: OR 0.29, 95% CI: 0.12–0.72, p = 0.0076; complete RV5 and RV1: 
OR 0.21 95% CI: 0.14–0.31, p < 0.0001) (Table 2). There was no increased risk of rotavirus 
disease, based on incomplete DTaP vaccine regimen (p = 0.9405). Children who had not 
received DTaP vaccination, however, were significantly at higher risk for rotavirus test-
positive disease (OR 2.18, 95% CI: 1.03–4.61, p = 0.0417). Although there was no increased 
risk for rotavirus test-positive disease among incomplete DTaP vaccines, the distribution of 
the RV vaccination status for complete and incomplete was significantly different between 
those who were complete for DTaP compared to those who were incomplete for DTaP (p < 
0.001): Among the 572 of 668 enrolled who had complete DTaP, 56.3% also were complete 
for RV vaccination by single vaccine type. In contrast, among the 67 with incomplete DTaP 
vaccination, over half (52.2%) received no RV vaccines, 37.3% had incomplete RV vaccines, 
and only 10.5% had received complete RV vaccines. We found similar significant 
differences in the distribution of RV vaccination status for race (p = 0.004), ethnicity (p < 
0.001) insurance (p = 0.0021), age categories (p = 0.0080), and AGE severity (p < 0.01) 
(Data not shown).
When controlling for age, race, ethnicity, insurance status, and disease severity, children who 
received a complete mixed types of rotavirus vaccines were no longer significantly more 
protected against rotavirus test-positive disease when compared to children with no vaccine 
(OR 0.46; 95% CI: 0.17–1.21, p = 0.1130). In contrast, receiving a complete rotavirus 
vaccine regimen of a single type (RV1 or RV5) was protective against rotavirus when 
compared to children with no vaccine (OR 0.22; 95% CI: 0.0.15–0.34, p < 0.0001). 
Similarly, receiving an incomplete vaccine regimen of a single or mixed types of rotavirus 
vaccine was also protective against rotavirus test-positive AGE (incomplete mixed vaccine 
types: OR 0.13; 95% CI: 0.04–0.35, p < 0.0001; incomplete RV1 or RV5: OR 0.32; 95% CI: 
0.18–0.56, p = 0.0001) (Table 3).
3.3. Severity of acute gastroenteritis disease
Density curves among cases for diarrheal severity were not different overall among those 
who received complete vaccination by mixed types or single type of rotavirus vaccines (Fig. 
4). Moreover, the density curves for severity for cases were also similar to controls, 
regardless of the classification of vaccination status. Average Vesikari scores for complete 
mixed or single vaccine type for cases did not show significant differences (Fig. 4). Average 
Vesikari score was 10 for cases (complete mixed, n = 7) and 9.75 for controls (complete 
mixed, n = 20, p = 0.8438). There was no significant difference in the average Vesikari score 
between complete mixed versus complete single vaccine type (p = 0.5397).
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In 2008, the ACIP recommended that children for whom the same type of rotavirus vaccine 
was unavailable at follow-up rotavirus vaccine visits receive a total of three doses of mixed 
type vaccine [4]. This recommendation was put in place to address potential issues that 
might exist with changes in provider supply, changes in the physician practice vaccination 
policies or patients’ access to provider practices. Data has been lacking about the vaccine 
effectiveness in situations which require mixed vaccine type usage. We found similar 
protective effect from rotavirus test-positive disease between complete mixed or combined 
dosing, and complete RV5 or RV1. Even with adjusting for age, race, ethnicity, insurance 
status, and disease severity, this protective effect persisted among those with complete single 
vaccine type or incomplete single or incomplete mixed type vaccination. Our observation 
suggests rotavirus vaccine regimens using complete mixed vaccine types also provided 
protection, but the numbers were too small to achieve statistical significance.
We also found that children who received incomplete doses of a single RV vaccine were 
protected against rotavirus AGE, similar to children who received complete RV vaccine 
doses. Our study is consistent with others who have reported that incomplete vaccination 
with rotavirus does protect against disease [25]. Furthermore, incomplete vaccination seems 
to confer sufficient immunity, and hence, protective effect from developing rotavirus AGE.
Although our sample size is too small to determine the impact of ‘complete mixed’ rotavirus 
vaccine on disease severity, we did find that the average disease severity score was less 
among those children who received any vaccination, regardless of whether it was complete 
mixed or single vaccine types. This suggests that some degree of protection in severe illness 
is afforded through vaccination using mixed vaccine types. This finding would support the 
completion of the rotavirus vaccine series with either RV5 or RV1 if the original vaccine 
could not be easily continued.
We saw similar rates of complete DTaP vaccination, regardless of the rotavirus vaccine type, 
suggesting that practitioners are more likely to adhere to this schedule with rotavirus 
vaccination, since it parallels the schedule for DTaP vaccination [26,27]. Panozzo et al. 
demonstrated in their study that the strongest predictor of rotavirus vaccine initiation was 
receipt of DTaP [27]. Other studies have shown similar findings with DTaP [28]. Although 
Panozzo et al. focused on infants who had private insurance, our study, which reflects a 
majority of infants who are receiving public insurance, found similar associations; this 
finding persisted even when we controlled for this co-variate. Similarly, it also appears that 
wide acceptance of rotavirus vaccination improves timeliness of other concomitantly 
scheduled routine vaccines [29]. Together, this suggests that intervention measures to 
increase vaccination rates of any one vaccine would result in the increase of vaccination 
rates for all vaccines.
We observed the same racial disparities in rotavirus vaccination and rotavirus related 
infection rates that have been previously reported [4,11,17,19–21,30,31]. However, our 
disparities were not limited to just those with rotavirus AGE, but also, we noted disparities 
among those who had diarrhea from other causes despite cases and controls being enrolled 
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from the same source population. We found that Hispanic participants were less likely to 
develop rotavirus disease compared to non-Hispanic participants. This has not been reported 
previously, and whether or not this finding is tied to cultural, geographic, or other 
confounding co-variates is not well understood and needs further investigation.
In the pre-rotavirus vaccination era, the majority of rotavirus disease requiring 
hospitalization occurred among children 6–24 months of age [32,33]. Rotavirus AGE was 
most prevalent among those who were older than 12 months of age in our study, which is 
consistent with predictions from a spatiotemporal model proposed by Pitzer et al. [10]. 
Despite the reported high rates of vaccine effectiveness demonstrated through the second 
year of life [11], we and others have observed an increasing age of rotavirus-related 
hospitalization [34]. The indirect benefits of rotavirus vaccination have been reported among 
the older unvaccinated children (>5 years) and adults [35–37]. Additional benefits worth 
exploring include the individual costs associated with shorter courses of vaccination 
compared to current vaccination schedules. The cost effectiveness from the societal 
perspective associated with such shortened rotavirus vaccination courses, which includes 
costs of vaccine delivery, cost savings from fewer provider visits, and fewer days lost from 
work by care givers is also likely to be favorable.
Important limitations include the geographic constraints of this study to children who live in 
urban, southeastern US. Our estimates for DTaP completion status may be underestimated as 
we applied the same criteria for complete vaccination status as was applied for rotavirus 
vaccination. Our analysis included only a small number of children who met the definition 
of complete mixed rotavirus vaccine type. Additional studies are needed to evaluate the 
effectiveness of mixed rotavirus vaccine regimens in parts of the country where circulating 
rotavirus genotypes vary. The number of individuals who had received incomplete 
vaccination and complete mixed schedules were small resulting in wide confidence intervals 
in the vaccine effectiveness estimates. Small sample sizes in these groups likely occurred as 
a result of manufacturer availability of the RV1 and RV5 vaccines. Because our study was a 
secondary analysis, we were limited by variables (age, race, ethnicity, insurance), postulated 
a priori to be associated with exposure (RV vaccination status), with too few participants in 
specific categories. This consequently limited our assessment of the impact these variables’ 
had on incomplete/complete RV vaccination status.
Few pediatricians administer mixed rotavirus vaccine regimens because it goes against ACIP 
guidelines. As such, there are currently no plans to extend this study. We did not factor in 
children <8 months of age who may not have had sufficient time to be fully vaccinated. We 
also did not exclude children who had previously had a rotavirus infection from the cases 
and control groups. This could have possibly presented bias into the study, particularly 
regarding disease severity. Possible selection bias could have occurred through the use of 
hospital controls instead of community controls. Similarly, legally authorized representatives 
of patients who declined participation in the study could also present selection bias. 
Additional studies are forthcoming from our NIH sponsored study (NCT01266850 examines 
the immunogenicity of different regimens: http://clinicaltrials.gov/ct2/show/NCT01266850?
term=rotavirus+and+vaccine+and+emory&rank=1.
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Because of the age restrictions in rotavirus vaccine administration guidelines, we observed 
that many of the rotavirus test-positive participants were not infants (>12 months), and 
approximately half of them had not previously received any rotavirus vaccines. This finding 
suggests that completion of rotavirus vaccination by administering a mixed rotavirus vaccine 
regimen to children does not compromise the effectiveness in preventing rotavirus-related 
diarrhea or increase the severity of disease. Incomplete rotavirus vaccines regimens also had 
similar effectiveness as complete vaccine regimens in preventing rotavirus disease. 
Physicians should work to ensure their patients receive their rotavirus vaccine according to 
the recommended schedule; however, a mixed vaccine type panel also appears to confer 
protection from disease. Incomplete and complete single-vaccine dosing provided protection 
against rotavirus test-positive AGE and also decreased the severity of rotavirus-related 
disease. Further research should be conducted to examine the effectiveness of mixed 
complete vaccine in protecting against rotavirus related conditions.
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Diagram of Patients Approached and Enrolled. From the 708 patients whose stool samples 
were collected, 10 individuals were excluded analysis due to not meeting enrollment criteria: 
one patient was younger than 55 days, three individuals had stool samples that were 
collected more than 14 days after enrollment, two patients had previously been enrolled in 
the study, and one patient was a twin whose twin sibling had been previously enrolled; three 
additional patients were excluded for not being in the state immunization registry and no 
provider vaccine record was provided. The majority of the legally authorized representatives 
who declined participation did so because they did not want to participate in research or for 
their child to submit a stool specimen.
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Epidemic curves for cases and controls for each year of rotavirus season. Cases were defined 
as test-positive rotavirus patients, and controls were defined as test-negative rotavirus 
patients.
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Density function of Vesikari scores. A score of 11 or higher on the Vesikari scale indicates 
severe disease.
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Density function of Vesikari scores of cases (Panel A) and controls (Panel B). A score of 11 
or higher on the Vesikari scale indicates severe disease. Participants in the complete single 
vaccine type group received either two doses of the RV1 vaccine or three doses of the RV5 
vaccine. Those in the complete mixed type vaccine group received two doses of the RV5 
vaccine and one dose of the RV1 vaccine.
Mohammed et al. Page 15

























Mohammed et al. Page 16
Table 1
Population characteristics.
Variables All n = 698 (%) Rotavirus positive n = 215 (%) Rotavirus negative n = 483 (%) p value
Age
<3 months 25 (3.6) 6 (2.8) 19 (3.9) <0.0005
3 to <6 months 93 (13.3) 14 (6.5) 79 (16.4)
6 to <9 months 125 (17.9) 23 (10.7) 102 (21.1)
9 to <12 months 100 (14.3) 21 (9.8) 79 (16.4)
12 to <24 months 232 (33.2) 93 (43.3) 139 (28.8)
>24 months 123 (17.6) 58 (27.0) 65 (13.5)
Gender
Male 408 (58.5) 131 (61.0) 277 (57.4) 0.38
Female 290 (41.5) 84 (39.1) 206 (42.7)
Race*
White 174 (24.9) 49 (22.8) 125 (25.9) 0.3981
Black 403 (57.7) 129 (60.0) 274 (56.7)
Other 80 (11.5) 28 (13.0) 52 (10.8)
Unknown 29 (4.2) 7 (3.3) 22 (4.6)
None 12 (1.7) 2 (0.9) 10 (2.1)
Ethnicity
Hispanic or Latino 134 (19.3) 27 (12.7) 107 (22.3) 0.0035
Not Hispanic or Latino 559 (80.7) 185 (87.3) 374 (77.8)
Insurance***
Private 86 (12.3) 39 (18.1) 47 (9.7) 0.01
Public 538 (77.1) 152 (70.7) 386 (80.0)
None 55 (7.9) 17 (7.9) 38 (7.9)
Other/Unknown 19 (2.4) 7 (3.3) 12 (2.5)
DTaP vaccine
No vaccine 29 (4.2) 14 (6.5) 15 (3.1) 0.11
Complete 600 (86.0) 180 (83.7) 420 (87.0)
Incomplete 69 (9.9) 21 (9.8) 48 (10.0)
Rotavirus vaccine type**
No vaccine 196 (29.3) 107 (50.7) 89 (19.4) 0.01
Complete RV5 or RV1 331 (49.0) 67 (31.8) 264 (57.5)
Complete mixed 27 (4.0) 7 (3.8) 20 (4.4)
Incomplete RV5 or RV1 86 (12.8) 25 (11.9) 61 (13.3)
Incomplete mixed 30 (4.5) 5 (2.4) 25 (5.5)
Severity of acute gastroenteritis (Vesikari score)
 Not severe (<11) 317 (45.4) 73 (34.0) 244 (49.5) <0.01
 Severe (≥11) 381 (54.6) 142 (66.0) 239 (50.5)
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*
For race, there were 80 categorized as ‘other’, which reflects Asian, American Indian/Alaskan Native, Native Hawaiian/Pacific Islander, or 
unknown. Forty-one (5.8%) participants had an unknown race, and five (0.7%) participants had an unknown ethnicity. The other category was 
reflective of 52 rotavirus negative controls and 28 rotavirus positive cases.
**
For vaccine types, there were 28 who had unknown vaccine types (4 were rotavirus positive cases and 22 were rotavirus negative controls).
***
For insurance, we combined the 17 participants with ‘other’ and ‘unknown’ status together: There were 0 ‘other’ and 7 ‘unknown’ among the 
rotavirus positive cases, and 2 ‘other’ and 8 ‘unknown’ among the rotavirus negative controls.
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Table 2
Risk factors associated with rotavirus test-positive disease.
Variables Disease status: rotavirus positive
OR 95% CI p value
Age
<3 months 1.00 Referent
3 to <6 months 0.56 0.19–1.65   0.2942
6 to <9 months 0.71 0.26–1.99   0.5189
9 to <12 months 0.84 0.30–2.37   0.7446
12 to <24 months 2.12 0.82–5.50   0.1232
>24 months 2.83 1.06–7.56   0.0385
Race
White 1.00 Referent
Black 1.20 0.81–1.78   0.3586
Other 1.37 0.78–2.42   0.2715
None/Unknown 0.72 0.32–1.61   0.4220
Ethnicity
Hispanic or Latino 1.00 Referent
Not Hispanic or Latino 1.96 1.24–3.10   0.0039
Insurance
Private 1.00 Referent
Public 0.47 0.30–0.75   0.0015
None 0.54 0.26–1.10   0.0891
Other/Unknown 0.84 0.29–2.42   0.7520
DTaP vaccine
Complete 1.00 Referent
Incomplete 1.02 0.60–1.76   0.9405
None 2.18 1.03–4.61   0.0417
Rotavirus vaccine type
No vaccine 1.00 Referent
Complete RV5 or RV1 0.21 0.14–0.31 <0.0001
Complete mixed 0.29 0.12–0.72   0.0076
Incomplete mixed 0.17 0.06–0.45   0.0004
Incomplete RV5 or RV1 0.34 0.20–0.59   0.0001
Acute gastroenteritis severity
Not severe 1.00 Referent
Severe 1.99 1.42–2.77 <0.0001
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Table 3
Multivariate analysis – controlling for disease severity, age, and insurance.
Variables Disease status: rotavirus positive
OR 95% CI p value
Vaccine type
None 1.00 Referent
Complete RV5 or RV1 0.22 0.15–0.34 <0.0001
Complete Mixed 0.46 0.17–1.21   0.1130
Incomplete Mixed 0.13 0.04–0.35 <0.0001
Incomplete RV5 or RV1 0.32 0.17–0.56 <0.0001
Participants in the complete RV5 category received three doses of vaccine. Those in the complete RV1 group received two doses of RV1 or two 
doses of RV1 and one dose of RV5. A complete mixed dose was defined as receiving one dose of RV1 and two doses of RV5. An incomplete mixed 
dose referred to participants who received only one dose of RV5 one dose of RV1. Participants in the incomplete RV5 group received either one or 
two doses of vaccine. Those in the incomplete RV1 group received only one dose of vaccine. There were 35 (5.0%) participants who received at 
least one rotavirus vaccine of an unknown type, and were, therefore, not included in the analysis.
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